icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
mNrA5E4JRZbZjB5g